Kairos Pharma Ltd. (NYSE American: KAPA) has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc. that would grant the company worldwide rights to two clinical-stage non-small cell lung cancer (NSCLC) assets. The proposed acquisition includes CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor.
The company stated that this acquisition would expand its oncology pipeline with late-preclinical and Phase 1-ready candidates designed to address EGFR mutations and MET-driven resistance mechanisms in NSCLC, which represents a multi-billion dollar market. Kairos indicated that dual inhibition of EGFR and MET pathways could overcome compensatory signaling and extend progression-free survival, positioning the assets for potential monotherapy and combination development pending completion of the transaction.
Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. To view the full press release, visit https://ibn.fm/MPrrW. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors, and more information can be found at https://www.BioMedWire.com.
This strategic move by Kairos Pharma represents a significant expansion of its oncology portfolio, particularly in the competitive NSCLC space where resistance mechanisms to existing therapies remain a major clinical challenge. The acquisition of both EGFR and MET inhibitors positions the company to potentially address two key pathways involved in cancer progression and treatment resistance simultaneously. For business leaders and investors in the biotechnology sector, this development highlights Kairos Pharma's growth strategy and pipeline diversification efforts in a high-value therapeutic area.
The transaction's completion would provide Kairos with assets at different stages of development, from pre-IND to Phase 1-ready, potentially accelerating the company's timeline to clinical milestones. The focus on overcoming drug resistance aligns with broader industry trends toward developing next-generation oncology therapies that address limitations of current treatments. As the global NSCLC market continues to grow, with increasing incidence and demand for more effective therapies, this acquisition could position Kairos Pharma more competitively within the oncology landscape.
